Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Larimar Therapeutics, Inc.

Insiders have been trading these 5 stocks: (($LRMR)), (($CYTK)), (($ITUB)), (($GLBE)) and (($IMVT)). Here is a breakdown of their recent trades and...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LRMR	$4.16	-0.95%	631.19K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LRMR	$4.16	-1.0%	631.19K
3
4
5
6

LRMR

LRMR

Get Larimar Therapeutics, Inc. Data in Excel

Get Larimar Therapeutics, Inc. Data in Excel